via Georgia State University
A novel form of macrophage-based immunotherapy is effective at treating a broad spectrum of cancers, including those at advanced stages, according to a groundbreaking study led by Georgia State immunology professor Yuan Liu.
Liu’s treatment works by leveraging macrophages, specialized white blood cells involved in the detection and elimination of cancer cells and other pathogens. Macrophages also activate T-cells which then attack and destroy cancer cells. Under normal conditions, this system works well to limit the growth of abnormal cells. However, cancer cells are tricky. Macrophages are vulnerable to cancer cells masquerading as healthy cells by co-opting mechanisms normal cells rely on that evade immune surveillance and detection. These mechanisms can profoundly increase cancer’s ability to grow and resist traditional treatment.
This new immunotherapy alters macrophages by knocking out Signal-regulatory protein ? (SIRP?), a receptor whose primary function is to prevent macrophages from engulfing and destroying healthy cells. Cancer cells often exploit SIRP? by expressing a marker (CD47) that disguises them as normal cells. In the animal study, published in Nature Communications, Liu and her team found that Sirp?-deficient macrophages initiate a robust immune response against cancer by triggering inflammation and activating tumor-specific T-cells.
The immune system is built to fight off invaders and aberrant cell growths like cancer. But cancer can also suppress and subvert the natural immune response by making it difficult for the body to recognize cancer cells as abnormal. While immunotherapy, which helps recruit the immune system to attack cancer cells, has revolutionized the treatment of tumors, the therapies only work for a limited number of patients.
“Scientists recognize that tumor-specific T-cells are the best weapon we have against cancer, but immunosuppression prevents them from doing their job,” Liu said. “Our treatment uses macrophages like a general to call up an army of T-cell soldiers to kill cancer.”
The study demonstrates the treatment is effective — and does not destroy large amounts of healthy cells — when delivered locally to the tumor site in conjunction with radiation therapy (RT), one of the cornerstone treatments for cancer.
“To kill the cancer without harming the patient, you need to localize the effects,” Liu said. “We developed a method that is very effective while minimizing the global adverse effects.”
The researchers found that local RT cured colorectal cancer and two types of pancreatic cancer in SIRP?-deficient mice with advanced tumors. The findings are significant, given that colorectal and pancreatic cancers are often treatment-resistant with high mortality rates.
The mice in the study developed inflammatory immune responses, and in most cases the tumors stopped growing immediately after irradiation. Within four to 12 days, mice with small and medium tumors had cleared the cancer completely, without apparent long-term adverse effects, and the animals remained tumor-free for the remainder of the study. In general, mice that were cured of their cancer exhibited similar longevity (about 18 months) as healthy mice.
The treatment also prevented one of the major negative effects of RT — its tendency to drive a strong wound-healing response that can result in the regrowth of cancer, as the local immune response is suppressed to promote new tissue growth and repair at the site of the RT. This mechanism, however, was absent post-RT in the SIRP?-deficient mice.
The mice exhibited long-lasting immunity to the cancer, which Koby Kidder, a Ph.D. student at Georgia State and co-author of the study, said is the result of an immune response robust enough to control the tumor cells throughout the body. Even when the cured mice were injected with new cancer cells, these cells failed to form tumors, suggesting the animals had acquired long-term immunity that prevented tumor recurrence.
“The reason we achieved such a high degree of efficacy is that we directly used the macrophage to mobilize other cells within the body,” Kidder said. “The mounting of a consummate anti-tumor immune response in concert with removing immunosuppressive factors (cells and cytokines) from the tumor microenvironment drastically affected the immune response. By removing SIRP? and combining it with radiotherapy, we elicited such a robust response it essentially cured the cancer.”
The study demonstrates SIRP? is a master controller of immunity inside the tumor microenvironment, directing post-RT wound healing, strengthening immunosuppression, conferring treatment resistance and allowing the cancer to progress. In the absence of SIRP?, however, antitumor immune responses are significantly enhanced.
The treatment has the potential to become a “pan-cancer therapy,” meaning it could be used to cure a broad spectrum of cancers, including those at advanced stages with metastasis. The study provides strong proof-of-concept for developing Sirp?-negative macrophage-based cell therapies, Liu said.
The cell therapy approach has already been tested against the entire NCI-60 cancer panel — made up of 60 various human tumor cell lines representing leukemia, melanoma, lung, colon, brain, ovary, breast, prostate and kidney cancers — and has been found to be effective. The researchers are applying for approval of the therapy as an investigational new drug by the U.S. Food & Drug Administration and hope to begin human clinical trials in 2022.
Liu has received grants from the National Cancer Institute, the Georgia Research Alliance and Biolocity to support this research.
“Currently, the treatments using immune therapy only benefit a small percentage of patients,” Liu said. “This therapy has already proven effective in the laboratory and could be the key to fighting all types of cancer. This is basically a battlefield in the body, and if we are able to activate the proper delivery signals, our bodies win.”
Original Article: A Novel Form of Immunotherapy Developed by Georgia State Has the Potential to Revolutionize Cancer Treatment
More from: Georgia State University
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Immune therapy
- Takeda Commits $100M for Chance to Bring Immunotherapy to Alzheimer’s Disease
Takeda Pharmaceutical has secured an option on an Alzheimer’s disease immunotherapy from AC Immune that is on track to report its first Phase 2 data later this quarter. Exercising the option would ...
- Therapeutic opportunities for hypermutated urothelial carcinomas beyond immunotherapy
In an editorial, in Oncoscience titled "Therapeutic opportunities for hypermutated urothelial carcinomas beyond immunotherapy," researcher Ioannis A. Voutsadakis from Sault Area Hospital and Northern ...
- Takeda Inks Potential $2.2B Deal for AC Immune’s Alzheimer’s Immunotherapy
Takeda on Monday said it is paying AC Immune $100 million upfront for an option on a Phase Ib/II Alzheimer’s disease candidate that could activate the immune system to clear amyloid beta plaques.
- AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s DiseaseTakeda to ...
- Could Cancer Vaccines Be the Next Big Breakthrough in Immunotherapy?
The race is on to develop therapeutic cancer vaccines that could give immunotherapies an edge, and late-stage trials could soon provide more-robust data about candidates’ efficacy and safety.
Go deeper with Google Headlines on:
Immune therapy
[google_news title=”” keyword=”immune therapy” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Macrophage-based immunotherapy
- Therapeutic opportunities for hypermutated urothelial carcinomas beyond immunotherapy
"Combinatorial approaches based on immunotherapy and targeting additional molecular defects, that are present in urothelial carcinomas, hold the hope for successful therapy of the sub-set of immune ...
- Combination immunotherapy treatment enhances immune response for people with malignant gliomas
Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have pinpointed a combination immunotherapy treatment that enhances the immune response for people with malignant gliomas, an ...
- Can Vitamin D Improve Cancer Immunotherapy?
The microbiome could also be an important factor in improving checkpoint inhibitors, an antibody-based immunotherapy used to treat several types of cancers. Altogether, these findings suggest a ...
- Immunotherapy and hay fever
Hope is at hand, however, in the form of immunotherapy. The most acute hay fever sufferers are sometimes referred for the treatment, and now new research "highlighting its effectiveness" may lead ...
- Combining the 'best of two worlds' to boost immunotherapy response in mice with breast cancer
A new type of immunotherapy drug appears to be more effective ... strategies to make small protein fragments or peptide-based therapy that may be complementary as an existing therapy.” ...
Go deeper with Google Headlines on:
Macrophage based immunotherapy
[google_news title=”” keyword=”macrophage based immunotherapy” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]